Global Alcohol Use Disorder (AUD) Report 2022 – Insights, Epidemiology and Market Forecasts 2019-2032 Featuring Odyssey pharmaceuticals, Merck Sante & MediciNova – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Alcohol Use Disorder (AUD) – Market Insight, Epidemiology and Market Forecast -2032” report has been added to ResearchAndMarkets.com’s offering.

This “Alcohol Use Disorder (AUD)- Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Alcohol Use Disorder (AUD), historical and forecasted epidemiology as well as the Alcohol Use Disorder (AUD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Alcohol Use Disorder (AUD) market report provides current treatment practices, emerging drugs, Alcohol Use Disorder (AUD) market share of the individual therapies, current and forecasted Alcohol Use Disorder (AUD) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Alcohol Use Disorder (AUD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Alcohol Use Disorder (AUD) Epidemiology

The Alcohol Use Disorder (AUD) epidemiology division provide insights into the historical and current Alcohol Use Disorder (AUD) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Alcohol Use Disorder (AUD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Alcohol Use Disorder (AUD) Epidemiology

The epidemiology segment also provides the Alcohol Use Disorder (AUD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Alcohol Use Disorder (AUD) Drug Chapters

The drug chapter segment of the Alcohol Use Disorder (AUD) report encloses the detailed analysis of Alcohol Use Disorder (AUD) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Alcohol Use Disorder (AUD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Alcohol Use Disorder (AUD) treatment.

Alcohol Use Disorder (AUD) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Alcohol Use Disorder (AUD) treatment.

Alcohol Use Disorder (AUD) Market Outlook

The Alcohol Use Disorder (AUD) market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Alcohol Use Disorder (AUD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of the Alcohol Use Disorder (AUD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Alcohol Use Disorder (AUD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Alcohol Use Disorder (AUD) market or expected to get launched in the market during the study period 2019-2032. The analysis covers Alcohol Use Disorder (AUD) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Competitive Intelligence Analysis

The publisher performs Competitive and Market Intelligence analysis of the Alcohol Use Disorder (AUD) Market by using various Competitive Intelligence tools that include – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability

Report Highlights

• In the coming years, Alcohol Use Disorder (AUD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Alcohol Use Disorder (AUD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Alcohol Use Disorder (AUD). Launch of emerging therapies will significantly impact the Alcohol Use Disorder (AUD) market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Alcohol Use Disorder (AUD)
• The in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Companies Mentioned

• Merck Sante
• Odyssey pharmaceuticals
• Dupont
• MediciNova
• Adial Pharmaceuticals
• Tonix Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/r04pox

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900